Michelle Rojas, MD
Family Medicine · Columbia, SCNPI 1205806718
Payments from drug & device makers
Across 382 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Gilead$894
- Novo Nordisk$690
- AstraZeneca$533
- Pfizer$296
- Sanofi-aventis U.S. LLC$292
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,404100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 65 | $1,193 |
| Gilead | 52 | $894 |
| Novo Nordisk | 40 | $690 |
| AstraZeneca | 35 | $533 |
| Pfizer | 19 | $296 |
| Sanofi-aventis U.S. LLC | 20 | $292 |
| Lilly USA, LLC | 17 | $274 |
| Insulet Corporation | 10 | $249 |
| AbbVie | 19 | $228 |
| Abbott | 11 | $189 |
| Merck | 16 | $173 |
| Novartis | 8 | $155 |
| Amgen | 8 | $148 |
| Johnson & Johnson | 9 | $135 |
| Boehringer Ingelheim | 8 | $134 |
| Mannkind Corporation | 6 | $98 |
| Astellas Pharma US Inc | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| Renalytix AI, Inc. | 4 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| GSK | 3 | $63 |
| Forte Bio-pharma LLC | 1 | $54 |
| Dexcom, Inc. | 2 | $52 |
| Napo Pharmaceuticals Inc | 3 | $41 |
| Exact Sciences | 2 | $39 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Braeburn Inc. | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Theratechnologies Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
How this compares
$6,404 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 192 | $750,988 |
| DovatoDolutegravir Sodium/Lamivudine | 90 | $257,629 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 63 | $233,874 |
| CabenuvaCabotegravir/Rilpivirine | 30 | $164,725 |
| JulucaDolutegravir/Rilpivirine | 29 | $102,302 |
| TrulicityDulaglutide | 78 | $99,852 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 24 | $93,422 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 17 | $68,029 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 14 | $67,161 |
| MounjaroTirzepatide | 60 | $59,350 |
| OzempicSemaglutide | 38 | $38,841 |
| PrezcobixDarunavir/Cobicistat | 14 | $34,491 |
| JanuviaSitagliptin Phosphate | 29 | $34,077 |
| RybelsusSemaglutide | 12 | $25,145 |
| JardianceEmpagliflozin | 15 | $23,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Dovato, Cabenuva, Juluca | $1,193 | $1,275,644341 claims |
| GileadBiktarvy, Genvoya | $894 | $161,45241 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $274 | $159,202138 claims |
| MerckJanuvia, Isentress, Janumet | $173 | $67,49664 claims |
| Novo NordiskOzempic, Rybelsus | $690 | $63,98650 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $135 | $42,70227 claims |
| Boehringer IngelheimJardiance, Tradjenta | $134 | $35,45328 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $63 | $24,96440 claims |
| AstraZenecaFarxiga | $533 | $22,49826 claims |
| AbbVieLinzess | $228 | $15,89320 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $14,66723 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $292 | $13,01216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Columbia
- Conigliaro JonesColumbia$552K
- Damon DanielsColumbia$300K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Terry NagelColumbia$112K
- Steven BarnettColumbia$33K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.